Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 2, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 3, 2026
OfficerOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001231589-26-000009
Filed / recorded
Apr 3, 2026, 12:36 AM UTC
Added to OQRO
Oct 6, 2026, 9:34 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
UNITED THERAPEUTICS Corp
Issuer CIK
1082554
Ticker
UTHR
Reporting person
Paul A Mahon
Relationship
Officer
Officer title
EVP & GENERAL COUNSEL
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Apr 2, 2026
Transaction code
M
Shares / units
8,300
Price per share
$146.03
Acquired / disposed
Acquired (A)
Shares owned after
53,472
Ownership form
Direct
Amendment
No
Footnotes from the filing
This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
“On July 22, 2026, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board.”